English
Linda Mileshkin
1.1K posts
Linda Mileshkin
@LindaMileshkin
Medical Oncologist, Gynaecological and Lung Cancers, Carcinoma of Unknown Primary. Views are entirely my own
Melbourne, Victoria Katılım Eylül 2016
384 Takip Edilen1.2K Takipçiler
Thrilled to present 5 posters at #IGCS2025, including 3 as first author! 🙌
Huge thanks to my amazing mentors, co-authors, WOCC, and patients for their invaluable support. This wouldn't be possible without you! 🙏
#NoWomanLeftBehind
#IGCS2025
English
QAM
Well done on a great presentation of the @anzgog ECHO trial by Sandy Hayes at #IGCS2025 this am. Why were the results different from the Challenge trial? Reassuring for women having chemo for ovarian cancer to know that if they don’t feeling like walking every day it is ok!
Angeles Secord@AngelesSecord
#IGCS2025 Congratulations Dr. Hayes!! Even though exercise did not improve PFS or OS or physical well being it was an amazing study and effort!! 🥰❤️🥰 still hopeful that exercise programs can improve outcomes for some. Still work to do!!
English
The discussant @ShannonWestin intrigued by the OS curves in the ECHO trial which although not significant currently may improve with time. Also pointing out that PFS was excellent in both arms.
Linda Mileshkin@LindaMileshkin
Well done on a great presentation of the @anzgog ECHO trial by Sandy Hayes at #IGCS2025 this am. Why were the results different from the Challenge trial? Reassuring for women having chemo for ovarian cancer to know that if they don’t feeling like walking every day it is ok!
English
Linda Mileshkin retweetledi
Peter Mac has joined @AAMRI_Aus and other research institutes around Australia to support calls for more medical research funding. The 'Half the Funding, Half the Future' campaign wants more funds for research into things like the fight against cancer - bit.ly/3LlUS9X
English
People shouldn’t have to choose inferior treatments for women with Gynaecological cancers because of lack of access to working radiotherapy machines and staff to operate them in Africa - as as being highlighted at the #IGCS2025 meeting in Cape Town
English
Dr Jason Wright from @greenjrnl encouraging people to keep trying to get your paper published even if initially rejected. Don’t perseverate, consider the peer reviewer comments, just revise and re-submit! @IGCSociety #igcs2025
English
So excited to be in Cape Town for the start of the @IGCSociety Annual Global meeting. Starting with a journal publication workshop highlighting the discrepancy between where most Gynae cancers occur vs where publications come from
English
@DrMHofman @myESMO @LouiseKostos @TheLancetOncol You must be kidding? Surely not in this day and age
English
@myESMO #ESMO25 ⭐ PhD @LouiseKostos flew 24 hrs with her 3 month old baby from Melbourne to Berlin to present #AlphaBet co-published in @TheLancetOncol ... Denied entry to conference - under 18s not allowed including babies! Thoughts?
Michael Hofman@DrMHofman
The AlphaBet trial @PeterMacCC @TheLancetOncol release today @myESMO #ESMO25: combining Lu-177 PSMA-I&T + Ra-223 in men with metastatic castration-resistant #ProstateCancer is safe, feasible, and active. ✅ No dose-limiting toxicities 💪 PSA-50% decline in 55% 🧬 Supports future α+β theranostic combos. 🔗 authors.elsevier.com/a/1lyc65EIIgTS… Congrats @LouiseKostos: what an amazing PhD! Thank-you to @PCF_Science @pros_tic @Bayer for funding & support, co-senior author @AzadOncology, all the co-authors, wider village of contributors and most importantly our patients and their families for participating.
Berlin, Germany 🇩🇪 English
Linda Mileshkin retweetledi
✨ There’s still time to register! Don’t miss the chance to join us in beautiful Cape Town for IGCS 2025 — a city of culture, diversity, and breathtaking landscapes. 🌍✈️ #IGCS2025 #CapeTown
igcsmeeting.com/register-now/
English
English
English
Linda Mileshkin retweetledi
Here in Canada, Prof. Senan reminds us of an urban myth. 🇨🇦 #SABRCAN25 ascopubs.org/doi/10.1200/JC…
English
Really proud for @ANZGOG and #APGOT to have been involved with this practice changing study for women with platinum resistant ovarian cancer! @PeterMacCC
The Lancet@TheLancet
📄 Presented at #ASCO25 “Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial” hubs.ly/Q03q9P6H0 1️⃣ Figure 2: Efficacy findings comparing relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy for progression-free survival 2️⃣ Figure 3: Efficacy findings comparing relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy for the interim overall survival analysis
English
Linda Mileshkin retweetledi
📄 Presented at #ASCO25
“Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial”
hubs.ly/Q03q9P6H0
1️⃣ Figure 2: Efficacy findings comparing relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy for progression-free survival
2️⃣ Figure 3: Efficacy findings comparing relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy for the interim overall survival analysis
English
Linda Mileshkin retweetledi
🧬 New research in @Nature shows advanced genomic testing can help more people with #Cancer of Unknown Primary get targeted treatment & identify where their cancer started.
Led by @GenCancerCentre a joint venture of @unimelb & @PeterMacCC.
🔗 petermac.org/about-us/news-…
English
Linda Mileshkin retweetledi
U.S. Sees Huge Drop in Cervical Precancers medpagetoday.com/hematologyonco…
this is because of vaccines - the HPV vaccine works. It prevents pre cancers which prevents cancers AND by preventing pre cancers - we avoid excisional procedures to treat pre cancers that can result in pregnancy complications. It is all a win. I am an oncologist - I don't want to treat your cervix cancer. I don't want you or your child to ever need me. Prevention is the best cure for cancer.
English
Looking forward to helping develop a great meeting!
IGCS@IGCSociety
We are thrilled to announce the Scientific Co-Chairs for #IGCS2025! @LindaMileshkin and @SakethGuntupal1 will oversee the development of the scientific program, ensuring an interdisciplinary, high-quality program in the latest advancements in gynecologic oncology.
English
@DrKatyMoore Why do you think @DrKatyMoore when OS positive in SOLO1 and PAOLA?
English
The long awaited PRIMA OS presented today by Dr. Antonio Gonzalez-Martin! No difference in OS in all comers or in any subgroup. Importantly no deficit noted either. Use of subsequent therapy and subsequent PARPi was high and - along with long term post progression survival will impact OS. @myESMO
English
@DrKatyMoore Definitely agree - particularly when all other similar studies using PD-1/PDL-1 in ovarian cancer. Definitely time to try something new!
English
ATALANTE OS: I'm going to respectfully disagree with the messaging of this presentation. This was a negative trial. PFS was negative. A "clinically meaningful" OS benefit does not make this a positive trial nor should encourage use of CPI in ovarian cancer. If anything - ATHENA and JAVELIN 100 - both of which suggested harm - should give us caution. Let's discuss....
English